Literature DB >> 31296503

Trends in Quality of Care for Patients with CKD in the United States.

Sri Lekha Tummalapalli1,2, Neil R Powe2,3, Salomeh Keyhani2,4.   

Abstract

BACKGROUND AND OBJECTIVES: Improving the quality of CKD care has important public health implications to delay disease progression and prevent ESKD. National trends of the quality of CKD care are not well established. Furthermore, it is unknown whether gaps in quality of care are due to lack of physician awareness of CKD status of patients or other factors. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a national, serial, cross-sectional study of visits to office-based ambulatory care practices for adults with diagnosed CKD from the years 2006 to 2014. We assessed the following quality indicators: (1) BP measurement, (2) uncontrolled hypertension, (3) uncontrolled diabetes, (4) angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among patients with hypertension, (5) statin use if age ≥50 years old, and (6) nonsteroidal anti-inflammatory drug use. Using multivariable linear regression and chi-squared analysis, we examined the change in quality performance over time.
RESULTS: Between 2006 and 2014, there were 7099 unweighted visits for patients with CKD representing 186,961,565 weighted visits. There was no difference in the prevalence of uncontrolled hypertension (>130/80 mm Hg) over time (46% in 2006-2008 versus 48% in 2012-2014; P=0.50). There was a high prevalence of uncontrolled diabetes in 2012-2014 (40% for hemoglobin A1c >7%). The prevalence of ACEi/ARB use decreased from 45% in 2006-2008 to 36% in 2012-2014, which did not reach statistical significance (P=0.07). Statin use in patients with CKD who were 50 years or older was low and remained unchanged from 29% in 2006-2008 to 31% in 2012-2014 (P=0.92).
CONCLUSIONS: In a nationally representative dataset, we found that patients with CKD had a high prevalence of uncontrolled hypertension and diabetes and a low use of statins that did not improve over time and was not concordant with guidelines.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  Ambulatory Care; CKD; Cross-Sectional Studies; Disease Progression; Glycated Hemoglobin A; Guidelines; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Linear Models; Prevalence; Public Health; Quality Improvement; Quality of Care; Renal Insufficiency, Chronic; blood pressure; diabetes mellitus; hypertension

Year:  2019        PMID: 31296503      PMCID: PMC6682807          DOI: 10.2215/CJN.00060119

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  21 in total

1.  A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Konstantina Tsogka; Evdokia Nikolaou; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2020-05-02       Impact factor: 2.370

2.  Advancing American Kidney Health: Perspective from Fresenius Medical Care.

Authors:  Robert J Kossmann; Eric D Weinhandl
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-08       Impact factor: 8.237

3.  Value-Based Kidney Care: Aligning Metrics and Incentives to Improve the Health of People with Kidney Disease.

Authors:  Pranav S Garimella; Daniel E Weiner
Journal:  J Am Soc Nephrol       Date:  2019-11-14       Impact factor: 10.121

4.  Tribute to Barbara Murphy.

Authors:  Steven G Coca
Journal:  Kidney360       Date:  2021-08-06

5.  Markers of Kidney Tubular Secretion and Risk of Adverse Events in SPRINT Participants with CKD.

Authors:  Alexander L Bullen; Simon B Ascher; Rebecca Scherzer; Pranav S Garimella; Ronit Katz; Stein I Hallan; Alfred K Cheung; Kalani L Raphael; Michelle M Estrella; Vasantha K Jotwani; Rakesh Malhotra; Jesse C Seegmiller; Michael G Shlipak; Joachim H Ix
Journal:  J Am Soc Nephrol       Date:  2022-08-16       Impact factor: 14.978

6.  Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.

Authors:  Min Zhuo; Jiahua Li; Leo F Buckley; Sri Lekha Tummalapalli; David B Mount; David J R Steele; David J Lucier; Mallika L Mendu
Journal:  Kidney360       Date:  2022-01-19

7.  A Quality Improvement Initiative Targeting Chronic Kidney Disease Metrics Through Increased Urinary Albumin Testing.

Authors:  Ken J Park; Robert S Unitan; Micah L Thorp
Journal:  Perm J       Date:  2020-12

8.  Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study.

Authors:  Ian E McCoy; Jialin Han; Maria E Montez-Rath; Glenn M Chertow
Journal:  Mayo Clin Proc       Date:  2021-05-02       Impact factor: 11.104

9.  Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria.

Authors:  Chi D Chu; Neil R Powe; Charles E McCulloch; Tanushree Banerjee; Deidra C Crews; Rajiv Saran; Jennifer Bragg-Gresham; Hal Morgenstern; Meda E Pavkov; Sharon H Saydah; Delphine S Tuot
Journal:  Hypertension       Date:  2020-11-16       Impact factor: 10.190

10.  Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.

Authors:  Lili Chan; Girish N Nadkarni; Fergus Fleming; James R McCullough; Patricia Connolly; Gohar Mosoyan; Fadi El Salem; Michael W Kattan; Joseph A Vassalotti; Barbara Murphy; Michael J Donovan; Steven G Coca; Scott M Damrauer
Journal:  Diabetologia       Date:  2021-04-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.